Club Biomed's second Virtual Portfolio--RANDOM WALK--
(current portfolio is on the E*Trade Site):
Portfolio Rules
History
Portfolio
Stock
|
purchase
|
sell date, amount, profit or loss
|
Vertex (VRTX)
|
300 @ 16.47 = $4941; July 2002
|
Feb 2003; $3675 (-$1266)
|
Cyanotech (CYAN)
|
8330 @ .60 = $4998; July 2002
|
June 2003: 4831 (-167)
|
Angiotech Pharm (ANPI)
|
125 @ 39.83; Sept 2002
|
|
Gene Logic (GLGC)
|
660@7.60: Sept 2002
|
|
Johnson & Johnson (JNJ
|
84 @ 59.35; Oct 2002
|
|
Cell Therapeutics (CTIC)
|
1000 @ 5.04 ; Oct 2002
|
|
Tanox (TNX)
|
440 @ 11.60; Nov 2002
|
|
Tularik TLRK)
|
540 @ 9.24 ; Nov 2002
|
|
Quintiles Transnational (QTRN)
|
380 @ 13.09; Jan 2003
|
|
Imclone (IMCL)
|
430 @ 11.65 ; Jan 2003
|
|
Diversa (DVSA)
|
700 @ 7.19, Feb 2003
|
March 2003: $6405 (+ $1,372)
|
King Pharmaceuticals (KG)
|
300 @ 15.91; Feb 2003
|
|
Sepracore (SEPR)
|
360@13.65: Mar 2003
|
|
Nuvelo (NUVO)
|
5900@0.85; MAR 2003
|
|
AVIGEN (AVGN)
|
1400@3.64 = 5096; JUNE 2003
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Date/ stock
|
Cash added (or removed)
|
gain or (loss) from sale
|
Feb 2003; VRTX
|
3675
|
(1266)
|
Mar 2003: DVSA
|
6405
|
$1,372
|
June 2003: CYAN
|
4831
|
(167)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Rules for constructing the Club Biomed
Virtual Portfolio:
- Begin with a list of stocks including the list generated by
John and other Partners in the Spring of 2002, add the list
followed by briefing.com, but double up on the big cap stocks as a
nod to market value. Add the stocks from value line. Pick stocks
at random. Buy and sell them as follows:
- For 5 meetings, pick two stocks to purchase each meeting for 5
meetings.
- Each purchase will be for about $5000, rounded to the nearest
multiple of 10 shares.
- For the next 5 meetings, pick two stocks to buy and then pick
one stock to sell. The portfolio is now 15 securities.
- After that, pick one stock to buy and then pick one stock to
sell each meeting.
-
- The portfolio will be given enough money to purchase the
initial portfolio of 15 stocks, as the money is required. Selling
5 stocks during the second five weeks should generate a cash
position of about $25,000 (5 x $5000).
- After that the cash value of the portfolio will be the value
gained from selling stocks, dividend income, and interest income
(at an interest rate of 0.1% per meeting (about 1.0% per year).
- If the cash position of the portfolio falls below 5000, only
the sell part of the discipline can be implemented until the cash
value is greater than $5000. If the cash position grows to more
than $30,000 then $6,000 of each new stock will be purchased until
the cash position falls below $15,000. If the cash position grows
to more than $35,000 then $7,000 of each new stock will be
purchased, etc.
- The positions of the portfolio will be kept on the E*Trade
site. The total value of the portfolio will be calculated and
posted at each meeting.
- If a company goes out of business, we will remove it from the
list of stocks that might be purchased.
- This portfolio will serve as another benchmark of our
performance.
The list of stocks used to generate the
Random Portfolio is below.
History:
After a spurt by Cyan that resulted in a 16% gain in early
augusst, Cyan reverted to its purchase price. Vertex dropped at
first, but gained with the Aug rally. By Sept 4 the protfolio had a
6.82% gain, which was due only to a change in Vertex.
By October the portfolio was off about 6% and VRTX was the only
winner. We added JNJ and CTIC for a total of siz stocks. This
portfolio is close to the mutual fund benchmark, which is also down
6%.
We added TLRK and TNOX in November. The portfolio is up, largely
due to a huge surge in CTIC, which is up dramaticallyIt has had some
sucess with a novel cancer target. VRTX continues to do well.
In January, 2003, we added IMCL and QTRN. The portfolio is now
down 7.67%. Everything is down except CTIC. We have reached 10
stocks, so we will start buying two and selling one for the next 5
months. QTRN is a contract organization and their stock price has
increased substaintially for the last few months.
In Feb 2003, we added Diversa and king Pharmeceuticals and sold
Vertex. The sale generated a loss of $1266, but created a cash
ballance, which is listed in a new table (above).
The quick turn around of Diversa netted a nice profit. we added
Sepracore, which is on an up trend and Nuvelo. We had picked Hyseq
Inc. but that company vanished in a merger, so I added the new
company. It has a low share price and a larger per share loss each
year.
Meetings were too croweded in April and May to make changes. In
june we sold Syan, which was a wash. We bought AVGN, which had a
spirt, but seems to bee loosing its postion.
The list of Stocks used to generate
the Random Portfolio:
- Vertex
- Novartis
- Bristol-Myers Squibb
- Imclone
- AstraZeneca
- Immunex
- Biogen
- Chiron
- Genentech
- Ligand
- Regeneron
- Amgen
- Merk
- Millennium
- Sepracor
- Ivax Corp
- Pfizer
- Teva Pharmaceutical
- Protein Design Labs
- Albany Medical Research
- Cephalon
- Tularik
- IDEC Pharmeceuticals
- Laboratory Corp of America
- Biomet
- Sigma Aldrich
- St Jude Medical
- Ameripath
- Gene Logic INC
- GENZYME
- Cell Genesys
- Corixa
- Medarex
- XOMA
- CuraGen Corp
- Amgen (AMGN)
- American Home Products (AHP)
- Bristol-Myers Squibb (BMY)
- Forest Labs (FRX)
- GlaxoSmithKline (GSK)
- ICN Pharmaceuticals (ICN)
- Johnson & Johnson (JNJ)
- Eli Lilly (LLY)
- Merck (MRK)
- Mylan Labs (MYL)
- Novartis AG (NVS)
- Pfizer (PFE)
- Schering Plough (SGP)
- Pharmicia (PHA)
- Teva Pharmaceuticals (TEVA)
- Watson Pharmaceuticals (WPI).
- Abgenix (ABGX)
- Affymetrix (AFFX)
- Avigen (AVGN)
- Biogen (BGEN)
- Celera (CRA)
- Cell Genesys (CEGE)
- Celgene (CELG)
- Cephalon (CEPH)
- Chiron (CHIR)
- Curagen (CRGN)
- Gene Logic (GLGC)
- Genentech (DNA)
- Genome Therapeutics (GENE)
- Genzyme (GENZ)
- Gilead Sciences (GILD)
- Human Genome Sciences (HGSI)
- ICOS Corp (ICOS)
- IDEC Pharmaceuticals (IDPH)
- Idexx (IDXX)
- Incyte Pharmaceuticals (INCY)
- Isis Pharmaceuticals (ISIP)
- Ligand Pharmaceuticals (LGND)
- Luminex (LMNX)
- Medarex (MEDX)
- Millennium (MLNM)
- Myriad Genetics (MYGN)
- Onyx (ONXX)
- Orchid BioScience (ORCH)
- Protein Design Labs (PDLI)
- Regeneron (REGN)
- Sepracor (SEPR)
- SuperGen (SUPG)
- Vical (VICL)
- Amgen (AMGN)
- American Home Products (AHP)
- Bristol-Myers Squibb (BMY)
- Forest Labs (FRX)
- GlaxoSmithKline (GSK)
- ICN Pharmaceuticals (ICN)
- Johnson & Johnson (JNJ)
- Eli Lilly (LLY)
- Merck (MRK)
- Mylan Labs (MYL)
- Novartis AG (NVS)
- Pfizer (PFE)
- Schering Plough (SGP)
- Pharmicia (PHA)
- Teva Pharmaceuticals (TEVA)
- Watson Pharmaceuticals (WPI). Abgenix, Inc.
- Adolor Corp
- Advanced Magnetics
- Albany Molecular
- Alexion Pharm Inc
- Alkermes Inc.
- Alliance Pharmaceutical Corp
- Amylin Pharm.
- Andrx Group
- Angiotech Pharm. Inc.
- Antigenics Inc.
- ArQule Inc
- AutoImmune Inc.
- Avant Immunotherapeutics
- AVI BioPharma Inc
- Avigen Inc
- Barr Labs.
- Bentley Pharmaceuticals Inc
- BioCryst Pharm Inc.
- BioMarin Pharmaceutical Inc
- Biopure Corp
- BioReliance Corp
- Biosite Diagnostics
- Biovail Corp.
- Bone Care Intl Inc
- Boron Lepore
- Bristol-Myers Squibb
- Carrington Labs
- Cell Genesys
- Cell Pathways Inc New
- Cell Therapeutic
- Cephalon Inc.
- Cerus Corp
- Chiron Corp.
- Collateral Therapeutics Inc
- Columbia Labs
- Corixa Corp
- Corvas Intl Inc.
- Covance Inc.
- Cubist Pharm Inc
- CuraGen Corp
- Curis Inc.
- CV Therapeutics
- Cyanotech Corp.
- Cygnus Inc.
- deCODE genetics, Inc.
- Discovery Partners Intl Inc
- Diversa Corp
- Elan Corp. ADR
- Emisphere Tech. Inc.
- Endo Pharmaceuticals Holdings
- EntreMed Inc
- Enzon Inc.
- Epimmune Inc.
- First Horizon Pharmaceutical
- Forest Labs.
- Genaera Corp
- Gene Logic Inc
- Genencor Intl Inc
- Genome Therapeutics Inc.
- Genzyme Corp.
- Geron Corp
- Gilead Sciences
- GlaxoSmithKline ADR
- Guilford Pharmaceutical
- Hi-Tech Pharm.
- Hyseq Inc
- ICN Pharmaceuticals
- ICOS Corp.
- IDEC Pharmac.
- ILEX Oncology
- ImClone Systems
- Immucor
- Immune Response Corp
- ImmunoGen Inc.
- Indevus Pharmaceuticals Inc
- Inhale Therapeutic
- IVAX Corp.
- K-V Pharmaceutical
- King Pharmac.
- Kosan Biosciences Inc
- Lexicon Genetics Inc
- Ligand Pharmaceuticals
- Lilly (Eli)
- Lynx Therapeutics Inc
- Maxim Pharmaceuticals
- Maxygen Inc
- Medarex, Inc.
- Medicis Pharmac.
- MedImmune Inc.
- Merck & Co.
- MGI Pharma
- Miravant Med Tech
- Mylan Labs.
- NBTY Inc.
- NeoRx Corp.
- Neurocrine Biosci.
- Neurogen Corp
- Novartis AG ADR
- Noven Pharm.
- NPS Pharmaceuticals
- Nutrition 21 Inc
- OraSure Technologies Inc
- OSI Pharmaceuticals
- Pain Therapeutics Inc
- PAREXEL Int'l
- Perrigo Co.
- Pfizer, Inc.
- Pharm. Resources Inc
- Pharmac. Product
- Pharmacia Corp.
- Pharmacyclics
- PRAECIS Pharmaceuticals Inc
- Progenics Pharmaceuticals
- Protein Design
- Quintiles Transn'l
- Salix Pharmaceuticals Ltd
- SangStat Med Corp
- Schering-Plough
- SciClone Pharm.
- Scios Inc.
- Sepracor, Inc.
- SEQUENOM Inc
- Serologicals Corp.
- SICOR Inc.
- Sonus Pharm Inc
- SuperGen Inc
- Tanox Inc
- Targeted Genetics Corp
- Theragenics Corp.
- Titan Pharm Inc
- Triangle Pharma Inc
- Trimeris Inc
- Tularik Inc.
- Versicor Inc
- Vical Inc.
- ViroPharma Inc
- Vivus Inc.
- Watson Pharmac.
- Wyeth
- XOMA Ltd
- Zila Inc.
- Zonagen Inc.
-